Cereno Scientific submits request to the FDA for “compassionate use” of CS1 for treatment of patients with rare disease Pulmonary Arterial Hypertension (PAH)
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that the company has submitted a request to the FDA for Expanded Access, sometimes called “compassionate use”, to investigational drug CS1 for use in an extension of the ongoing Phase II trial evaluating CS1 in PAH. The initiative is prompted by a request from an investigator in the ongoing Phase II study. Cereno has submitted a request to the FDA under the ‘Expanded Access to Investigational Drugs for Treatment Use’ for expanded access to CS1,